Michael Gelband’s Serina Therapeutics SER Stock Holding History

Michael Gelband’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-525	Closed	-$75K	–	1367
2019 Q1	$75K	Buy	+525	New	+$76.8K	0.01%	625

Other funds holding SER

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Michael Gelband's SER Position: Q2 2019 in Review

Michael Gelband sold out of Serina Therapeutics (SER) in Q2 2019, closing a stake of 525 shares — an estimated $75K sold.

Michael Gelband first reported a position in SER in Q1 2019 and held it in 1 quarter. The position peaked at $75K in Q1 2019. 51 funds tracked by Wall St. Rank hold SER as of Q2 2019.

Michael Gelband reported no remaining Serina Therapeutics position as of Q2 2019 after selling out during the quarter.
Michael Gelband sold 525 Serina Therapeutics shares in Q2 2019, an estimated $75K.
Michael Gelband first reported a position in Serina Therapeutics in Q1 2019 and held it in 1 quarter.
Michael Gelband's Serina Therapeutics position peaked at $75K in Q1 2019.
51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2019.

Based on ExodusPoint Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.